13F Data
13F filer · CIK 2052213

Elmind Capital, LP

NEW YORK, NY · filing since Q4 2025 · last filing Aug 14, 2026
Reported value
$338.9M
Positions
34
New / sold out
34 / 0
Added / reduced
0 / 0
Turnover
–
buys $338.9M · sells $0
Top-10 weight
68.5%

No 13F for Q3 2025, so every position this quarter shows as new.

Biggest buys vs Q3 2025

ChangeSecurityShares changeChange %Est. trade value
NewCOGENT BIOSCIENCES INC+1,170,740–+$41.6M
NewSYNDAX PHARMACEUTICALS INC+1,855,000–+$39.0M
NewVIRIDIAN THERAPEUTICS INC+858,631–+$26.7M
NewVERA THERAPEUTICS INC+482,500–+$24.4M
NewCELLDEX THERAPEUTICS INC NEW+865,000–+$23.5M
NewCG ONCOLOGY INC+492,500–+$20.4M
NewBIOCRYST PHARMACEUTICALS INC+2,150,000–+$16.8M
NewVAXCYTE INC+291,500–+$13.4M
NewBEAM THERAPEUTICS INC+476,338–+$13.2M
NewPHARVARIS N V+475,750–+$13.2M
24 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q3 2025

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $338.9MQ1 2026: $352.2MQ2 2026: $398.0M
Q4 2025Q2 2026

Holdings · Q4 2025

#SecuritySharesValueWeight
1COGENT BIOSCIENCES INCCOM1,170,740$41.6M12.27%
2SYNDAX PHARMACEUTICALS INCCOM1,855,000$39.0M11.50%
3VIRIDIAN THERAPEUTICS INCCOM858,631$26.7M7.89%
4VERA THERAPEUTICS INCCL A482,500$24.4M7.21%
5CELLDEX THERAPEUTICS INC NEWCOM NEW865,000$23.5M6.93%
6CG ONCOLOGY INCCOM492,500$20.4M6.03%
7BIOCRYST PHARMACEUTICALS INCCOM2,150,000$16.8M4.95%
8VAXCYTE INCCOM291,500$13.4M3.97%
9BEAM THERAPEUTICS INCCOM476,338$13.2M3.90%
10PHARVARIS N VCOM475,750$13.2M3.90%
24 more rows. Subscribe for $29/month to see every row, download the data and use the API.